Cabazitaxel 183133-96-2 Jevtana
Hengxun pharmaceutical is a leading manufacturer and supplier of chemicals in China. We develop, produce and distribute high quality pharmaceuticals, intermediates, special chemicals and other fine chemicals.
We could give you:
1.Best quality in your requirement
2.Competitive price in China market
3.mature Technical support
4.Professional logistic support
All we want is win-win business. Send yr. inquiries, you will get it!
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View